Nanosphere, Inc., (Nasdaq:NSPH), announced today it was selected one of the world's most innovative companies by Massachusetts Institute of Technology's Technology Review with its inclusion on the 2010 TR50 list.
The 2010 TR50 is Technology Review's first annual list identifying companies that demonstrate the most impressive and noteworthy innovations occurring in technology.
"In choosing the TR50, we picked companies with this year's most important inventions and breakthroughs. But we also selected companies that are successfully growing businesses and markets around innovative new products," said Jason Pontin, editor in chief and publisher of Technology Review. "The TR50 list is our selection of companies that show the most impressive innovation in commercializing new technologies."
"Nanosphere is a leader in commercializing microfluidic technology for use in clinical diagnostic tests, helping to pave the way for personalized medicine. The FDA's recent approval of its instrument for pharmacogenomic testing is a significant milestone," said David Rotman, editor, Technology Review.
Nanosphere joins such notable companies chosen by MIT's Technology Review as Amazon, GlaxoSmithKline, Google, Tesla Motors, and Twitter. It is one of six public bio-medical companies listed.
"To be recognized as an innovative global leader furthering healthcare and personalized medicine is gratifying," said William P. Moffitt, president and chief executive officer of Nanosphere, Inc. "Our focus on achieving excellence will continue to generate new solutions and breakthroughs that will improve diagnostic testing and ultimately the diagnosis and treatment of disease and the health of people worldwide."
The additional five selected public biomedical companies include Alnylam, AthenaHealth, GlaxoSmithKline, Illumina, and Medtronic. The list also acknowledged five private biomedicine companies including BIND Biosciences, Complete Genomics, Fate Therapeutics, Fluidigm, and Pacific Biosciences.
Nanosphere was also featured in the March/April edition of Technology Review, with a focus on the company's Verigene® System, troponin testing and overall approach to personalized medicine.